Circulating DNA in Surgically Treated NSCLC

NCT ID: NCT04037150

Last Updated: 2019-08-06

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 100 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2019-07-01
• Study Completion Date: 2020-12-31

Brief Summary

• The investigators will prospectively recruit 100 NSCLC patients. The cfDNA samples will be gathered before the surgery and postoperatively 4-6 weeks after surgery and at 6 and 12 months follow-up visits.
• This study aims to investigate the role of ctDNA in NSCLC patients treated with curative intent surgery.
• Preoperative ctDNA will be compared to primary tumor DNA to investigate the concordance of mutations and gained mutations from possible primary tumor cancer stem cell.
• Preoperative ctDNA findings will be tested for associations with baseline characteristics as well as clinically important factors such as TNM stage, histopathological findings, and tumor volume.
• The investigators aim to identify molecular residual disease (MRD) using multiple ctDNA samples after the surgery and search the associations with clinical recurrence and survival, with possible correlation to palliative chemotherapy response
• Using multiple ctDNA samples, the investigators will gather information about tumor heterogeneity, diversity of disease genotypes, and dynamic changes in ctDNA.
• If additional data from palliative immunotherapy (PD-L1 inhibitors) is available, the effect of this will be evaluated in the study.

Detailed Description

Plasma liquid biopsy is rapidly emerging non-invasive diagnostic tool that could be used as a surrogate for tumor biopsy or disease activity. Circulating cell-free DNA (cfDNA) is short fragment double stranded DNA that is present in blood. Ultrasensitive mutation specific techniques based on polymerase-chain-reaction (PCR) analysis are required to detect mutations and alterations in circulating tumor cells. Early studies based on a small number of patients indicate that ctDNA analyses could be used for molecular testing, cancer detection, surrogate for tumor burden or activity, and treatment monitoring in solid tumors.

In the current study the role of ctDNA from plasma in surgically treated early stage NSCLC patients will be investigated. The investigators aim to collect a prospective cohort of a hundred patients with preoperative and follow-up samples as well as diagnostic tissue specimen. The investigators hypothesize that longitudinal ctDNA-samples could be used as prognostic marker for recurrence and survival. Finding postsurgical positive ctDNA could aid us to identify patients who would benefit from adjuvant chemotherapy before clinical recurrence.

Study design and ethical considerations

This is a prospective, non-interventional, single arm study that will be conducted in collaboration with Helsinki Biobank. It is estimated that cohort of 100 patients will provide with ample sample size, as 30-40% will develop a recurrence during the 5 year follow up. A preliminary agreement with Helsinki Biobank about the sample collection and storage has been made. There will be no additional study appointments as all the control visits and study samples are scheduled according to normal clinical protocol. The patients will be recruited from 1.5.2019 to 31.12.2020. The recruited patients will provide both a written informed consent for this study and a Helsinki Biobank consent that covers plasma and surgical samples. Participants can withdraw the consent at any time of the study. The Biobank samples will be taken simultaneously with clinical samples, minimizing the additional harm to participants. A Helsinki University Hospital (HUS) institution review board permission (HUS 60/2019) and ethical statement has been granted (455/2019). The study will be conducted in accordance with the Declaration of Helsinki.

Patients

The patients are recruited prior to surgery from preoperative multidisciplinary team (MDT) meeting. The inclusion criteria into this study is histologically confirmed NSCLC eligible for surgical treatment and naïve for systemic oncological treatments with either formalin-fixed paraffin-embedded tissue or fresh frozen tissue sample available.

The clinical patient data will be collected from electronic medical records (EMR) at each point of time (e.g. preoperative, operative, follow-up). Each patient is evaluated in MDT meetings before and after the surgery, where the both the clinical and the pathological stage is determined. In addition, radiological consolidation/tumor ratio will be calculated from preoperative computerized tomography (CT) scans. This data will be transferred to a secure, certified electronic database (Granitics Unify Med) with access only by group researchers.

Blood and tissue sample collection

The blood and tissue samples will be taken simultaneously with clinical samples. The investigators aim to collect surgically removed tissue samples as well as preoperative and follow-up cfDNA samples from all patients. In addition to surgical samples, tissue samples will be collected from metastatic lesions including autopsy samples in deceased patients. If not already taken, the standard Biobank blood sample will be taken simultaneously to preoperative samples.

Plasma samples will be taken at the time of the patient's clinical blood samples. A preoperative sample will be taken 1-2 day before the surgery. The first post-operative follow-up sample will be taken at the surgical visit 4-6 weeks after the operation. The second and third follow-up samples will be taken at 6 and 12 months during clinical follow-up visit. At each time point, cfDNA samples will be collected into duplicate specialized collection tubes containing fixatives to stabilize DNA from fragmentation (2 x 10ml Streck cfDNA BCT). Blood sample will be centrifuged to extract plasma. Plasma and tissue samples will be stored at -80 celsius in Helsinki Biobank.

Study outcomes Preoperative ctDNA mutations will be matched to clinically important endpoints such as disease-free survival, tumor size, histology, TNM-stage, and overall survival. The clinical cancer recurrence will be obtained from radiological or tumor tissue samples. Disease free survival will be assessed from surgery to disease recurrence in MDT meetings or death. Overall survival is assessed from surgery to death as a result of any cause.

Genetic analysis

Quantitative and mutation specific ctDNA analysis will be made via tumor/somatic exome genome panel that includes 23.000 gene panel with 50 million bases. Germline DNA isolation will be done from buffy coat taken from patients' blood sample (B-Bio-0). Firstly, to achieve true somatic mutations the germline variation is deleted from the ctDNA. Secondly, ctDNA will be compared to tumor tissue DNA mutations to exclude false positive findings. Thirdly, similar or new mutations collected from follow-up samples will be used to detect postsurgical residual disease or cancer recurrence.

The sequencing will be done in collaboration with Institute for Molecular Medicine Finland (FIMM), with their proprietary gene paneling.

Conditions

Non-small Cell Lung Cancer

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Interventions

Circulating tumor DNA

Circulating tumor DNA

Intervention Type: DIAGNOSTIC_TEST

Eligibility Criteria

Exclusion Criteria

• prior metastatic solid cancer, hematological malignancy, known hereditary cancer syndrome, and pregnancy

• Minimum Eligible Age: 20 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Institute for Molecular Medicine

OTHER

Sponsor Role: collaborator

Helsinki University Central Hospital

OTHER

Sponsor Role: lead

Responsible Party

Ilkka Ilonen

Principal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Ilkka Ilonen, PhD

Role: PRINCIPAL_INVESTIGATOR

Helsinki University Central Hospital

Locations

Helsinki University Central Hospital

Helsinki, Uusimaa, Finland

Site Status: RECRUITING

Countries

Finland

Central Contacts

Eva Sutinen, BSC

Role: CONTACT

eva.sutinen@hus.fi

+358505840449

Juuso Paajanen, MD

Role: CONTACT

juuso.paajanen@hus.fi

Facility Contacts

Eva Sutinen, BSC

Role: primary

eva.sutinen@hus.fi

Juuso Paajanen, MD

Role: backup

juuso.paajanen@hus.fi

+358504270071

Other Identifiers

Y2019SK007

Identifier Type: -

Identifier Source: org_study_id